<DOC>
	<DOCNO>NCT01108445</DOCNO>
	<brief_summary>To compare anti-tumor activity everolimus sunitinib subject metastatic renal cell carcinoma ( mRCC ) non-clear cell pathology .</brief_summary>
	<brief_title>Phase II Study Afinitor vs. Sutent Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma</brief_title>
	<detailed_description>This international ( USA , Canada , UK ) open-label , outpatient , multicenter , randomize study treatment RAD001 ( everolimus ( Afinitor® ) sunitinib ( Sutent® ) subject mRCC non-clear cell histology . Special emphasis place papillary chromophobe histology sarcomatoid clear cell variant , medullary , collect duct carcinoma exclude ( see eligibility ) . Subjects may continue receive study drug disease progression , unacceptable toxicity , withdrawal consent , maximum 24 month . Continuation study assign treatment allow beyond 24 month discretion sponsor . Stratification variable include histology ( papillary vs. chromophobe ) Motzer risk criterion ( 0 , 1-2 , 3 ) . Tumor progression assess locally independent review , strict accordance Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) criterion measure every 12 week . At time progression , subject take study simple administrative mortality follow-up . Primary pathologic sample plasma/urine angiokine level baseline time collect store centrally biomarker analysis .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Histologically confirm advanced Renal Cell Carcinoma ( RCC ) , nonclear cell pathology . 2 . RCC tumor tissue available correlative science , either primary metastatic site . 3 . At time screen , least 4 week since prior palliative radiation therapy and/or major surgery , resolution toxic effect prior therapy National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ; version 4.0 ) Grade 1 . 4 . Subject must radiographic evidence metastatic disease least 1 measurable per RECIST 1.1 criterion ( Attachment 1 ) ] . 5 . Age &gt; 18 year . 6 . Adequate laboratory value 7 . Karnofsky Performance Status ≥ 60 ( Attachment 2 ) . 8 . Life expectancy least 3 month . 9 . Written , sign , date , witness Institutional Review Board ( IRB ) Institutional Ethics Committee ( IEC ) approve informed consent form ( ICF ) screening procedure perform . 1 . Subjects history active central nervous system ( CNS ) metastases . 2 . Prior systemic therapy RCC , include mTOR antiangiogenic therapy , chemotherapy , biologic experimental therapy . 3 . Subjects collect duct , medullary , small cell , oncocytoma , lymphomatype pathology . 4 . Subjects receive know strong CYP3A4 isoenzyme inhibitor and/or inducer . 5 . Major surgery , open biopsy , traumatic injury , radiotherapy within 4 week screen visit . 6 . Subjects recover prior biopsy , surgery , traumatic injury , and/or radiation therapy . 7 . Presence nonhealing wound ulcer . 8 . Grade 3 hemorrhage within past month . 9 . Hypertension systolic blood pressure &gt; 180 mm Hg and/or diastolic pressure &gt; 100 mm Hg . 10 . Subjects American Heart Association ( AHA ) Class 24 heart disease history congestive heart failure ejection fraction &lt; 50 % , history unstable angina , myocardial infarction , coronary artery bypass graft , cerebrovascular accident , transient ischemic attack , pulmonary embolism within 6 month entry . 11 . Diabetes mellitus glycosylated hemoglobin A1c ( HbgA1c ) &gt; 10 % despite therapy . 12 . A history interstitial pneumonitis . 13 . Subjects active autoimmune disorder ( ) treat immunosuppressive agent within 4 week prior screen visit . 14 . Subjects receive immunosuppressive agent chronic viral/bacterial/fungal illness human immunodeficiency virus ( HIV ) . 15 . Patients receive immunization attenuate live vaccine within one week study entry study period . 16 . Patients active infection ( ) , active antimicrobial therapy serious intercurrent illness . 17 . History prior malignancy past 5 year . 18 . Pregnant nursing woman . 19 . Major medical/psychiatric illness , investigator 's judgment , substantially increase risk associate subject 's participation study , include inability absorb oral medication history noncompliance medical regimen . 20 . Known hypersensitivity component everolimus sunitinib product 21 . Subjects take agent significantly prolong QTc interval eligible . 22 . Proteinuria spot urine protein/creatinine ratio &gt; 2 24 hour urine protein &gt; 2 gram per 24 hour . 23 . Severely impaired lung function define spirometry Carbon Monoxide Diffusing Capacity ( DLCO ) 50 % normal predict value and/or O2 saturation 88 % less rest room air . 24 . Advanced liver disease cirrhosis severe hepatic impairment ( ChildPugh class C ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>sutent</keyword>
	<keyword>everolimus</keyword>
	<keyword>renal cancer</keyword>
	<keyword>papillary renal cell</keyword>
	<keyword>chromophobe renal cell</keyword>
	<keyword>papillary</keyword>
	<keyword>chromophobe</keyword>
</DOC>